Insights

Strategic Focus Clinical-stage oncology company leveraging synthetic lethality and precision medicine to target cancer subtypes with unmet need, presenting opportunities to collaborate on target discovery, companion diagnostics, and combination therapies.

Targeted Partnerships Strong potential for collaborations with pharma and biotech to co-develop targets, evaluate biomarker-driven patient stratification, and accelerate progression of vopimetostat and related combos in MTAP deleted RAS mutant cancers.

Data & Insights Robust data engine based on DNA sequencing and CRISPR target discovery; opportunity to license or co-develop discovery platforms, analytics tools, and synthetic lethality networks to de-risk and speed clinical programs.

Commercial Readiness Recent Phase 1/2 data and upcoming ESMO presentations indicate enterprise value in strategic partnerships, with possible opportunities for co-promotion, regional access deals, or milestone-driven collaborations contingent on trial readouts.

Leadership & Execution Active management team engagement and board changes signal ongoing strategic pivots; prospect for advisory or investment-led partnerships, as well as opportunities to align with potential acquirers or large-cap collaborators seeking novel oncology modalities.

Similar companies to Tango Therapeutics

Tango Therapeutics Tech Stack

Tango Therapeutics uses 8 technology products and services including Power BI, Amazon Web Services, Squarespace, and more. Explore Tango Therapeutics's tech stack below.

Media & News

Tango Therapeutics's Email Address Formats

Tango Therapeutics uses at least 3 email formats:
Tango Therapeutics Email FormatsExamplePercentage
FLast@tangotx.comJDoe@tangotx.com
94%
First_L@tangotx.comJohn_D@tangotx.com
5%
First.Last@tangotx.comJohn.Doe@tangotx.com
1%

Frequently Asked Questions

What is Tango Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Tango Therapeutics is a publicly traded company; the company's stock symbol is TNGX.

What is Tango Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Tango Therapeutics's official website is tangotx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Tango Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Tango Therapeutics's annual revenue is estimated to be $50M - $100M.

What is Tango Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Tango Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Tango Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Tango Therapeutics has approximately 181 employees across 4 continents, including North America, Europe and Africa. Key team members include President And Ceo: M. P., Head Of Clinical Operations: S. P. and Head Of Immunology: M. G. Explore Tango Therapeutics's employee directory with LeadIQ.

What industry does Tango Therapeutics belong to?

Minus sign iconPlus sign icon
Tango Therapeutics operates in the Biotechnology Research industry.

What technology does Tango Therapeutics use?

Minus sign iconPlus sign icon
Tango Therapeutics's tech stack includes Power BI, Amazon Web Services, Squarespace, Google Cloud, DocuSign, Smartsheet, Greenhouse and Piwik PRO Core.

What is Tango Therapeutics's email format?

Minus sign iconPlus sign icon
Tango Therapeutics's email format typically follows the pattern of FLast@tangotx.com. Find more Tango Therapeutics email formats with LeadIQ.

How much funding has Tango Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Tango Therapeutics has raised $1.2B in funding. The last funding round occurred on Jun 09, 2026 for $197M.

When was Tango Therapeutics founded?

Minus sign iconPlus sign icon
Tango Therapeutics was founded in 2017.
Tango Therapeutics logo

Tango Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Tango Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on discovering novel drug targets and delivering precision cancer medicines. The company uses a discovery platform that combines DNA sequencing and CRISPR-based target discovery to identify cancer targets for therapeutic development. Tango concentrates on three areas of cancer biology - loss of tumor suppressor gene function, multiple oncogenic drivers, and immune evasion - each in patient populations with limited treatment options. Its approach centers on synthetic lethality, aiming to selectively induce cancer cell death while minimizing effects on normal cells. Founded in 2017 with a Series A led by Third Rock Ventures, Tango employs a staff of 51 to 200 people.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
TNGX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
51-200

Section iconFunding & Financials

  • $1.2B

    Tango Therapeutics has raised a total of $1.2B of funding over 7 rounds. Their latest funding round was raised on Jun 09, 2026 in the amount of $197M as a Post IPO Equity.

  • $50M - $100M

    Tango Therapeutics's revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.